

Electronic Acknowledgement Receipt

EFS ID:	7735947
Application Number:	09993647
International Application Number:	
Confirmation Number:	1010
Title of Invention:	omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
First Named Inventor/Applicant Name:	Bernd Riedl
Customer Number:	23599
Filer:	Csaba Henter/Caitlin Sickler
Filer Authorized By:	Csaba Henter
Attorney Docket Number:	BAYER 18A
Receipt Date:	03-JUN-2010
Filing Date:	27-NOV-2001
Time Stamp:	10:58:14
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	P295- WissnerAnaloguesofPlateletAct ivatingFactor.pdf	969644 fa7ee5668a7a642ff406ebcc1296254e448c3b49	no	11

Warnings:

Information:

2	NPL Documents	P296-Wojnowski-EndothelialApoptosis.pdf	684484	no	5
			7d47a551382c582f447f8bc802cefb2ed10d5e2c		
Warnings:					
Information:					
3	NPL Documents	P297-WOODETAL- NovelRAFKinaseInhibitorBay.pdf	105764	no	1
			41d558def82d4bbbc48298e9a20b76a1568a72a88		
Warnings:					
Information:					
4	NPL Documents	P298- WrightetalBovineimmunodeficiency.pdf	752630	no	12
			80eda3c6451cf23fb089f74bcd2eec26a7469058		
Warnings:					
Information:					
5	NPL Documents	P299- WrightClinicalTrialsOfBAY439006Part1ClinicalTrialsReferralResourceOncology.pdf	418875	no	4
			5110f9caac00834bdb1311b685a77c1dd5a1b8e0a		
Warnings:					
Information:					
6	NPL Documents	P299a-Wu-et-al-Int-J--Oncov-20-p509.pdf	744542	no	8
			4d02162c22633d9f05ad933fb90cf8312f65f9b5		
Warnings:					
Information:					
7	NPL Documents	P300-XU0133WO- HypoxiaElevation.pdf	944109	no	8
			0a484211c8b94ee1de1bdebe63a21b41fc78be72		
Warnings:					
Information:					
8	NPL Documents	P301-HEetal-Oral-Formulation-of-a-Novel-Antiviral-Agent-PG301029-in-a-mixture.pdf	90941	no	5
			0d098f948b01c1201ec1f717ec826c5d174db7a5		
Warnings:					
Information:					
9	NPL Documents	P301a- YamaguchietalHepatology.pdf	8358201	no	10
			fbe8e7f4ca9c347d5c3cb21669ab5ea5016ad2e6		
Warnings:					
Information:					
10	NPL Documents	P302- YangAktProteinKinaseBSignaling.pdf	570671	no	6
			dfa390de84d9fa348d9df25db033174c3fdff70b		
Warnings:					
Information:					

11	NPL Documents	P303- YangetalAntiviralChemotherap y.pdf	1025487 7ec056cbb63cedd5b48775cd8dec544c167 16ee7	no	9
Warnings:					
Information:					
12	NPL Documents	P304- YehetalCharSevereAccuteResp Syndrome.pdf	879554 a7dbffcbca34830a595abf16de94bdee3021 90b1	no	6
Warnings:					
Information:					
13	NPL Documents	P305-YUETAL-RoleofMcl1.pdf	261375 db72ff651f678030c99ba4199909f00573d 7c96	no	9
Warnings:					
Information:					
14	NPL Documents	P306- ZachosetalHerpedsimplexvirust ype1.pdf	975995 ba66bfb9a634cd7d397cf59f46170271cd3 9d72	no	7
Warnings:					
Information:					
15	NPL Documents	P306a-angari-et-al-Clin-Cancer- Res-v10-p88.pdf	1636031 3efc8262db10337e4d13bc127de34ebe1a3 05e69	no	8
Warnings:					
Information:					
16	NPL Documents	P307-NORDEN-Zfoni- BloodBasedBiomarkers.pdf	490747 00873d3997a663f8024347f32106621ec68c 8618	no	8
Warnings:					
Information:					
17	NPL Documents	P308- ZhaoetalModerateMutationRat e.pdf	727799 1c97a204fd88670596eb5bfc1fd61b522645 db51	no	9
Warnings:					
Information:					
18	NPL Documents	P309- ZHUETALFROMTHECYCLOOXIG ENASE2INHIBITORCELECOXIB. pdf	617853 82bb858938fa5eaca02ba8ec5618e94321 d7b4e	no	10
Warnings:					
Information:					
19	NPL Documents	P310- XP00145482CarteretalAntitum orEfficacy.pdf	56274 71531bdfc26247552f2d683484fc293694bf 6445	no	1
Warnings:					
Information:					

20	NPL Documents	P311- IwadataetalIntraArterialACNUC DDPChemotherapy.pdf	67923 687c02fbd08ad789c33c609a557d7f7a190fda46	no	1
----	---------------	---	---	----	---

Warnings:

Information:

Total Files Size (in bytes):	20378899
-------------------------------------	----------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.